Nuvation Bio, Inc.(NUVB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NUVB Nuvation Bio, Inc.

Not Yet Opened 01-15 16:00:00 EST

6.14

-0.17

-2.69%

盘后6.20

+0.06+0.98%

19:55 EST

High6.47	Low6.06	Vol5.53M
Open6.43	D1 Closing6.31	Amplitude6.50%
Mkt Cap2.10B	Tradable Cap1.42B	Total Shares342.83M
T/O34.26M	T/O Rate2.39%	Tradable Shares231.05M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"NUVB","market":"US","secType":"STK","nameCN":"Nuvation Bio, Inc.","latestPrice":6.14,"timestamp":1768510800000,"preClose":6.31,"halted":0,"volume":5529688,"hourTrading":{"tag":"盘后","latestPrice":6.1999,"preClose":6.14,"latestTime":"19:55 EST","volume":51994,"amount":319219.6434,"timestamp":1768524944255},"delay":0,"floatShares":231046340,"shares":342833433,"eps":-0.640012,"marketStatus":"Not Yet Opened","change":-0.17,"latestTime":"01-15 16:00:00 EST","open":6.43,"high":6.47,"low":6.06,"amount":34262590.503683,"amplitude":0.064976,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.640012,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1768554000000},"marketStatusCode":0,"adr":0,"exchange":"NYSE","adjPreClose":6.31,"preHourTrading":{"tag":"盘前","latestPrice":6.33,"preClose":6.31,"latestTime":"09:14 EST","volume":22053,"amount":140962.716457,"timestamp":1768486492597},"postHourTrading":{"tag":"盘后","latestPrice":6.1999,"preClose":6.14,"latestTime":"19:55 EST","volume":51994,"amount":319219.6434,"timestamp":1768524944255},"volumeRatio":0.645225,"optionData":{"bulkOrders":[{"symbol":"NUVB","call":true,"expireDate":1773979200000,"strike":"5.0","timestamp":1768490031303,"price":1.5,"volume":1500,"amount":225000,"type":"-"}]},"impliedVol":0.941,"impliedVolPercentile":0.3267},"requestUrl":"/m/hq/s/NUVB","defaultTab":"news","newsList":[{"id":"2603679638","title":"Wedbush Remains a Buy on Nuvation Bio (NUVB)","url":"https://stock-news.laohu8.com/highlight/detail?id=2603679638","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603679638?lang=en_us&edition=fundamental","pubTime":"2026-01-13 22:38","pubTimestamp":1768315094,"startTime":"0","endTime":"0","summary":"In a report released today, David Nierengarten from Wedbush maintained a Buy rating on Nuvation Bio, with a price target of $11.00. According to Ti...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wedbush-remains-a-buy-on-nuvation-bio-nuvb-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wedbush-remains-a-buy-on-nuvation-bio-nuvb-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","NUVB"],"gpt_icon":0},{"id":"2603068423","title":"Nuvation Bio shares attractive on weakness, says B. Riley","url":"https://stock-news.laohu8.com/highlight/detail?id=2603068423","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603068423?lang=en_us&edition=fundamental","pubTime":"2026-01-13 21:10","pubTimestamp":1768309828,"startTime":"0","endTime":"0","summary":"B. Riley views Nuvation Bio (NUVB) shares as attractive on weakness, despite a 20% selloff, following management’s updates on Monday, telling inves...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nuvation-bio-shares-attractive-on-weakness-says-b-riley-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nuvation-bio-shares-attractive-on-weakness-says-b-riley-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","NUVB"],"gpt_icon":0},{"id":"2603574115","title":"Analysts Offer Insights on Healthcare Companies: Nuvation Bio (NUVB), Mediwound (MDWD) and Argenx Se (ARGX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2603574115","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603574115?lang=en_us&edition=fundamental","pubTime":"2026-01-13 12:30","pubTimestamp":1768278618,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Nuvation Bio (NUVB – Research Report), Mediwound (MD...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-nuvation-bio-nuvb-mediwound-mdwd-and-argenx-se-argx-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-nuvation-bio-nuvb-mediwound-mdwd-and-argenx-se-argx-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0320765992.SGD","LU0109394709.USD","LU1983260115.SGD","BK4137","ARGX","LU0128526141.USD","IE00B4R5TH58.HKD","LU2324357040.USD","IE00BJT1NW94.SGD","BK4585","IE0009355771.USD","IE00BFTCPJ56.SGD","MDWD","BK4505","BK4581","BK4007","IE0002141913.USD","IE00BJJMRZ35.SGD","NUVB","LU0889565916.HKD","XBI","XLV","IE0034235188.USD","HCSG","LU0029874061.USD","BK4139","IE00B2B36J28.USD","BK4588","LABU"],"gpt_icon":0},{"id":"2603542831","title":"Nuvation Bio Shares Fall After Disappointing Sales Guidance for Lung-Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2603542831","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603542831?lang=en_us&edition=fundamental","pubTime":"2026-01-13 00:26","pubTimestamp":1768235160,"startTime":"0","endTime":"0","summary":"Nuvation Bio shares dipped after the oncology company issued preliminary sales numbers for Ibtrozi behind Wall Street's expectations.Shares fell 16% to $6.77 late Monday morning. The stock has more than doubled in value in the past year.The company said Monday that it expects to report net revenue from Ibtrozi, a treatment for non-small cell lung cancer, of $15.7 million in the fourth quarter and $24.7 million since the drug's commercial launch in the second quarter.Analysts surveyed by FactSet were anticipating $17.1 million in sales for the quarter and $26.1 million since the product launch.Nuvation said 216 patients had begun Ibtrozi treatment during the fourth quarter, exceeding the company's internal projections. It said that since Ibtrozi's launch, 432 patients have begun taking the treatment, representing a treatment adoption rate about six times greater than that of other similar drug launches, citing data from Iqvia.The company also said it received a $25 million milestone pay","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"Nuvation Bio Shares Fall After Disappointing Sales Guidance for Lung-Cancer Treatment","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NUVB","BK4007"],"gpt_icon":0},{"id":"2602821541","title":"Nuvation Bio falls -17.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2602821541","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602821541?lang=en_us&edition=fundamental","pubTime":"2026-01-12 23:06","pubTimestamp":1768230362,"startTime":"0","endTime":"0","summary":"Nuvation Bio (NUVB) is down -17.3%, or -$1.39 to $6.65. Published first on TheFly – the ultimate source for real-time, market-moving breaking finan...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nuvation-bio-falls-17-3-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nuvation-bio-falls-17-3-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","NUVB"],"gpt_icon":0},{"id":"2602431735","title":"Nuvation Bio price target lowered to $17 from $18 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2602431735","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602431735?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:56","pubTimestamp":1768226161,"startTime":"0","endTime":"0","summary":"H.C. Wainwright lowered the firm’s price target on Nuvation Bio (NUVB) to $17 from $18 and keeps a Buy rating on the shares. The firm says the comp...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nuvation-bio-price-target-lowered-to-17-from-18-at-h-c-wainwright-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nuvation-bio-price-target-lowered-to-17-from-18-at-h-c-wainwright-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NUVB","BK4007"],"gpt_icon":0},{"id":"2602609543","title":"Nuvation Bio Inc. : H.c. Wainwright Cuts Target Price to $17 From $18","url":"https://stock-news.laohu8.com/highlight/detail?id=2602609543","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602609543?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:55","pubTimestamp":1768226125,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nAZN4RXDYQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NUVB","BK4007"],"gpt_icon":0},{"id":"2602616548","title":"Nuvation Bio Inc. Highlights Oncology Pipeline and Global Strategy in New Corporate Presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2602616548","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602616548?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:29","pubTimestamp":1768224556,"startTime":"0","endTime":"0","summary":"Nuvation Bio Inc. has released a corporate presentation detailing recent developments in its oncology portfolio. The company highlighted the approval of IBTROZI , a next-generation ROS1 inhibitor, for advanced ROS1-positive non-small cell lung cancer  in the U.S., Japan, and China. Nuvation Bio also announced a strategic partnership with Eisai, granting Eisai exclusive rights to develop, register, and commercialize IBTROZI in Europe and additional territories outside the U.S., China, and Japan. The agreement includes an upfront payment of approximately $60 million, a near-term milestone payment of around $30 million upon conditional or full approval in Europe, and double-digit tiered royalties on net sales. In addition, the company is advancing safusidenib, a brain-penetrant mIDH1 inhibitor, in a pivotal study for high-grade and high-risk IDH1-mutant glioma. Nuvation Bio is also developing NUV-868, a BD2-selective BET inhibitor, and evaluating preclinical candidates from its proprietar","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL4rdNMS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NUVB"],"gpt_icon":0},{"id":"2602100775","title":"Nuvation Bio, Eisai enter exclusive taletrectinib license agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2602100775","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602100775?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:06","pubTimestamp":1768223197,"startTime":"0","endTime":"0","summary":"Nuvation Bio (NUVB) and Eisai (ESAIY) announced an exclusive license and collaboration agreement that significantly expands the long-term global fo...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nuvation-bio-eisai-enter-exclusive-taletrectinib-license-agreement-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nuvation-bio-eisai-enter-exclusive-taletrectinib-license-agreement-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","NUVB","ESAIY"],"gpt_icon":0},{"id":"2602510692","title":"Press Release: Nuvation Bio Reports Preliminary Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook Ahead of 44th Annual J.P. Morgan Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2602510692","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602510692?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:04","pubTimestamp":1768223040,"startTime":"0","endTime":"0","summary":"Successfully started 216 patients on IBTROZI  in the fourth quarter of 2025, for a total of 432 new patient starts since launch in the second half of June 2025. Preliminary IBTROZI net product revenue of approximately $15.7 million in the fourth quarter and $24.7 million since launch. Preliminary unaudited cash, cash equivalents and marketable securities of approximately $529.2 million as of December 31, 2025. Company to present at 44 Annual J.P. Morgan Healthcare Conference tomorrow, January 13, at 3:45 p.m. PT/6:45 p.m. ET. Nuvation Bio Inc. , a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced preliminary fourth quarter and full year 2025 net product revenue for IBTROZI  and provided a 2026 outlook ahead of its presentation at the 44 Annual J.P. Morgan Healthcare Conference in San Francisco, CA.Preliminary Fourth Quarter and Full Year 2025 Financial Results and IBTROZI Commercial Results. --  In the third quarter, the co","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","LU0795875169.SGD","LU0882574139.USD","LU0106831901.USD","LU1989772923.USD","IE00BKVL7J92.USD","LU0006306889.USD","IE00BZ1G4Q59.USD","BK4534","LU2357305700.SGD","LU1244550221.USD","NUVB","HCSG","LABU","LU0106261372.USD","LU0267386448.USD","LU1244550577.SGD","LU1720051108.HKD","XBI","LU0320765646.SGD","LU1074936037.SGD","BK4127","LU0029874061.USD","BK4585","LU0912757837.SGD","BK4504","LU2028103732.USD","LU1244550494.USD","LU1732799900.SGD","LU0314104364.USD","BK4588","CNS","LU0234570918.USD","R","LU1791710582.SGD","LU0128526141.USD","DDC","BK4581","BK4135","LU2271345857.HKD","BK4007","BK4212","LU2133065610.SGD","LU1162221912.USD","XLV","BK4516","LU0971096721.USD","LU2089284900.SGD","LU0557290698.USD","BK4232"],"gpt_icon":0},{"id":"2602105815","title":"Nuvation Bio Inc - Prelim Ibtrozi Net Product Revenue $15.7 Mln in Q4","url":"https://stock-news.laohu8.com/highlight/detail?id=2602105815","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602105815?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:00","pubTimestamp":1768222808,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nTUA705HN8:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NUVB","BK4007"],"gpt_icon":0},{"id":"2602517973","title":"Nuvation Bio and Eisai Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside U.S., China and Japan","url":"https://stock-news.laohu8.com/highlight/detail?id=2602517973","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602517973?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:50","pubTimestamp":1768222249,"startTime":"0","endTime":"0","summary":"Jan 12 (Reuters) - Nuvation Bio Inc ::*NUVATION BIO AND EISAI ENTER INTO EXCLUSIVE LICENSING AGREEMENT FOR TALETRECTINIB IN EUROPE AND ADDITIONAL COUNTRIES OUTSIDE U.S., CHINA AND JAPAN*NUVATION BIO I","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nRSD6MCkhj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NUVB"],"gpt_icon":0},{"id":"2602122335","title":"Nuvation Bio Signs Exclusive Licensing Agreement with Eisai for Taletrectinib","url":"https://stock-news.laohu8.com/highlight/detail?id=2602122335","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602122335?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:30","pubTimestamp":1768221044,"startTime":"0","endTime":"0","summary":"Nuvation Bio Inc. announced an exclusive license and collaboration agreement with Eisai Co., Ltd. for the global development, registration, and commercialization of taletrectinib outside the U.S., China, and Japan. Under the terms of the agreement, Nuvation Bio will receive an upfront payment of 50 million  and up to 145 million  in regulatory and commercial milestone payments, as well as double-digit tiered royalties up to the high-teens on future net sales in the licensed territories. Eisai will have exclusive rights to taletrectinib in Europe, the Middle East, North Africa, Russia, Turkey, Canada, Australia, New Zealand, Singapore, the Philippines, Indonesia, Thailand, Malaysia, Vietnam, and India. Nuvation Bio will retain full U.S. commercial rights and continue to lead global development of taletrectinib.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-ge","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDLbXjmC3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NUVB","BK4007"],"gpt_icon":0},{"id":"2602512290","title":"Nuvation Bio Inc: Maa for Treatment of Advanced Ros1+ Nsclc Is Expected to Be Filed in Europe in First Half of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2602512290","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602512290?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:30","pubTimestamp":1768221000,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nTUAK2JNF:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NUVB"],"gpt_icon":0},{"id":"2602512286","title":"Nuvation Bio Inc - to Receive up to €195 Mln in Payments","url":"https://stock-news.laohu8.com/highlight/detail?id=2602512286","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602512286?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:30","pubTimestamp":1768221000,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nTUAK2JNF:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NUVB","BK4007"],"gpt_icon":0},{"id":"2602351229","title":"Nuvation Bio Inc - Eisai Receives Exclusive Rights for Taletrectinib in Multiple Regions","url":"https://stock-news.laohu8.com/highlight/detail?id=2602351229","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602351229?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:30","pubTimestamp":1768221000,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nTUAK2JNF:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NUVB","BK4007"],"gpt_icon":0},{"id":"2602122165","title":"Nuvation Bio Inc - Maa for Taletrectinib Expected in Europe in 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2602122165","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602122165?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:30","pubTimestamp":1768221000,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nTUAK2JNF:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NUVB"],"gpt_icon":0},{"id":"2601386670","title":"Nuvation Bio Initiated at Neutral by UBS","url":"https://stock-news.laohu8.com/highlight/detail?id=2601386670","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601386670?lang=en_us&edition=fundamental","pubTime":"2026-01-08 04:34","pubTimestamp":1767818040,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NUVB/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 07, 2026 15:34 ET (20:34 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NUVB","BK4007"],"gpt_icon":0},{"id":"2601080485","title":"UBS Initiates Nuvation Bio at Neutral With $10 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2601080485","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601080485?lang=en_us&edition=fundamental","pubTime":"2026-01-07 22:53","pubTimestamp":1767797606,"startTime":"0","endTime":"0","summary":"Nuvation Bio (NUVB) has an average rating of buy and mean price target of $11.33, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","NUVB"],"gpt_icon":0},{"id":"2601806682","title":"Nuvation Bio Inc : UBS Initiates Coverage With Neutral Rating and Target Price  $10","url":"https://stock-news.laohu8.com/highlight/detail?id=2601806682","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601806682?lang=en_us&edition=fundamental","pubTime":"2026-01-07 21:51","pubTimestamp":1767793873,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nAZN4RRVZX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NUVB"],"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.2734},{"period":"1month","weight":-0.291},{"period":"3month","weight":0.8006},{"period":"6month","weight":1.6696},{"period":"1year","weight":1.3615},{"period":"ytd","weight":-0.3147}],"compareEarnings":[{"period":"1week","weight":0.004},{"period":"1month","weight":0.0197},{"period":"3month","weight":0.0419},{"period":"6month","weight":0.103},{"period":"1year","weight":0.1678},{"period":"ytd","weight":0.0151}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Nuvation Bio is a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates. Nuvation Bio's proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung , M.D., who previously founded Medivation, Inc., which brought to patients one of the world's leading prostate cancer medicines. Nuvation Bio has offices in New York and San Francisco .","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.083083},{"month":2,"riseRate":0.2,"avgChangeRate":-0.07924},{"month":3,"riseRate":0.6,"avgChangeRate":0.155399},{"month":4,"riseRate":0.4,"avgChangeRate":0.005292},{"month":5,"riseRate":0.6,"avgChangeRate":0.002702},{"month":6,"riseRate":0.2,"avgChangeRate":-0.090917},{"month":7,"riseRate":0.6,"avgChangeRate":0.065913},{"month":8,"riseRate":0.6,"avgChangeRate":0.013694},{"month":9,"riseRate":0.5,"avgChangeRate":-0.038205},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.016548},{"month":11,"riseRate":0.5,"avgChangeRate":0.163132},{"month":12,"riseRate":0.666667,"avgChangeRate":0.061496}],"exchange":"NYSE","name":"Nuvation Bio, Inc.","nameEN":"Nuvation Bio, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Nuvation Bio, Inc.(NUVB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Nuvation Bio, Inc.(NUVB) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Nuvation Bio, Inc.,NUVB,Nuvation Bio, Inc.股票,Nuvation Bio, Inc.股票老虎,Nuvation Bio, Inc.股票老虎国际,Nuvation Bio, Inc.行情,Nuvation Bio, Inc.股票行情,Nuvation Bio, Inc.股价,Nuvation Bio, Inc.股市,Nuvation Bio, Inc.股票价格,Nuvation Bio, Inc.股票交易,Nuvation Bio, Inc.股票购买,Nuvation Bio, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Nuvation Bio, Inc.(NUVB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Nuvation Bio, Inc.(NUVB) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction